Physician profile
Dilip Singh
NPI 1265886287
$1,182.42
in general payments reported to CMS, 2019-2025
22 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $239 · 2023: $324 · 2024: $381 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.40 | 2021-2025 | Botox |
| Stryker Corporation | $145.92 | 2023 | Trevo |
| Amgen INC. | $117.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $100.25 | 2022-2024 | Ultomiris, Soliris |
| Ucb, INC. | $99.15 | 2024-2025 | Rystiggo, Zilbrysq |
| Tanabe Pharma America, INC. | $71.05 | 2024-2025 | Radicava |
| Pfizer INC. | $68.73 | 2022-2024 | |
| Sk Life Science, INC. | $65.63 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $62.90 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $41.94 | 2023-2025 | Dysport |
| Lundbeck LLC | $32.43 | 2024 | Vyepti |
| Argenx US, INC. | $31.34 | 2024 | Vyvgart Hytrulo |
| Allergan, INC. | $25.02 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.68 | 2024 | Hyqvia |
| Greenwich Biosciences, INC. | $22.53 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.25 | 2022 | |
| Chiesi USA, INC. | $13.76 | 2025 | Cleviprex |
| Octapharma USA, INC. | $13.75 | 2024 | Panzyga |
| Janssen Pharmaceuticals, INC | $13.52 | 2021 | |
| Natus Medical Incorporated | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.